EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self‐samples and cervical scrapes

Birgit M M Wever iD, Rianne van den Helder iD, Annina P van Splunter, Mignon D J M van Gent, Jenneke C Kasius iD, Johannes W Trum, Harold R Verhoeve, Wilhelmina M van Baal iD, Alicia Hulbert iD, Lisanne Verhoef iD, Daniëlle A M Heideman, Birgit I Lissenberg-Witte iD und 3 weitere

International Journal of Cancer · 15.07.2023 · 153 (2) · 341-351

DOI: 10.1002/ijc.34504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 23.03.2023. Verfasst von Birgit M M Wever und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands. Hauptthemen laut MEDLINE: Uterine Cervical Neoplasms, Endometrial Neoplasms, Uterine Cervical Dysplasia, Papillomavirus Infections. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 45 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Hanarth Fonds, Stichting De Weijerhorst.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Endometrial cancer incidence is rising and current diagnostics often require invasive biopsy procedures. DNA methylation marker analysis of minimally‐ and non‐invasive sample types could provide an easy‐to‐apply and patient‐friendly alternative to determine cancer risk. Here, we compared the performance of DNA methylation markers to detect endometrial cancer in urine, cervicovaginal self‐samples and clinician‐taken cervical scrapes. Paired samples were collected from 103 patients diagnosed with stage I to IV endometrial cancer. Urine and self‐samples were collected at home. All samples were tested for nine DNA methylation markers using quantitative methylation‐specific PCR. Methylation levels measured in endometrial cancer patients were compared to unpaired samples of 317 healthy controls. Diagnostic performances were evaluated by univariable and multivariable logistic regression analysis, followed by leave‐one‐out cross‐validation. Each methylation marker showed significantly higher methylation levels in all sample types of endometrial cancer patients compared to healthy controls ( P < .01). Optimal three‐marker combinations demonstrated excellent diagnostic performances with area under the receiver operating curve values of 0.95 (95% CI: 0.92‐0.98), 0.94 (0.90‐0.97) and 0.97 (0.96‐0.99), for endometrial cancer detection in urine, self‐samples and scrapes, respectively. Sensitivities ranged from 89% to 93% at specificities of 90% to 92%. Virtually equal performances were obtained after cross‐validation and excellent diagnostic performances were maintained for stage I endometrial cancer detection. Our study shows the value of methylation analysis in patient‐friendly sample types for endometrial cancer detection of all stages. This approach has great potential to screen patient populations at risk for endometrial cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uterine Cervical NeoplasmsEndometrial NeoplasmsUterine Cervical DysplasiaPapillomavirus InfectionsFemaleHumansDNA MethylationCervix UteriBiopsy

Stichwörter der Autor:innen

DNA methylationcervical scrapeendometrial cancerurinevaginal sample

Autor:innen und Institutionen

  • Department of Pathology, Amsterdam UMC, location Vrije Universiteit Amsterdam, Amsterdam, The Netherlands.
  • Cancer Center Amsterdam, Imaging and Biomarkers, Amsterdam, The Netherlands.
  • Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Antoni van Leeuwenhoek/Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Gynecologic Oncology, Center of Gynecologic Oncology Amsterdam, Amsterdam UMC, location Amsterdam Medical Center, Amsterdam, The Netherlands.
  • Department of Obstetrics and Gynecology, OLVG, location Oost, Amsterdam, The Netherlands.
  • Department of Obstetrics and Gynecology, Flevo Hospital, Almere, The Netherlands.

ORCID-Profile: Birgit M M Wever, Rianne van den Helder, Jenneke C Kasius, Wilhelmina M van Baal, Alicia Hulbert, Lisanne Verhoef, Birgit I Lissenberg-Witte, Renske D M Steenbergen, Maaike C G Bleeker

Förderung

  • Hanarth Fonds
  • Stichting De Weijerhorst

Zitieren

APA

Wever, B. M. M., van den Helder, R., van Splunter, A. P., van Gent, M. D. J. M., Kasius, J. C., Trum, J. W., Verhoeve, H. R., van Baal, W. M., Hulbert, A., Verhoef, L., Heideman, D. A. M., Lissenberg-Witte, B. I., van Trommel, N. E., Steenbergen, R. D. M., & Bleeker, M. C. G. (2023). DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self‐samples and cervical scrapes. International Journal of Cancer, 153(2), 341-351. https://doi.org/10.1002/ijc.34504

Vancouver

Wever BMM, van den Helder R, van Splunter AP, van Gent MDJM, Kasius JC, Trum JW, et al. DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self‐samples and cervical scrapes. International Journal of Cancer. 2023;153(2):341-351. doi:10.1002/ijc.34504

BibTeX
@article{Wever2023,
  author = {Wever, Birgit M M and van den Helder, Rianne and van Splunter, Annina P and van Gent, Mignon D J M and Kasius, Jenneke C and Trum, Johannes W and Verhoeve, Harold R and van Baal, Wilhelmina M and Hulbert, Alicia and Verhoef, Lisanne and Heideman, Daniëlle A M and Lissenberg-Witte, Birgit I and van Trommel, Nienke E and Steenbergen, Renske D M and Bleeker, Maaike C G},
  title = {DNA methylation testing for endometrial cancer detection in urine, cervicovaginal self‐samples and cervical scrapes},
  journal = {International Journal of Cancer},
  year = {2023},
  volume = {153},
  number = {2},
  pages = {341--351},
  doi = {10.1002/ijc.34504}
}
Kostenlos starten →